ADVISORY, Aug. 18, 2015 (GLOBE NEWSWIRE) --
Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Patrick McEnany, Chief Executive Officer will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, August 19, 2015 – 3:45 p.m. to 4:00 p.m. ET
Catalyst Pharmaceuticals Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Catalyst Pharmaceuticals (Nasdaq:CPRX):
Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative therapies for people with rare debilitating diseases. Catalyst is developing Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton myasthenic syndrome (LEMS), a rare neuromuscular, autoimmune disorder that afflicts about 3,000 people in the U.S. LEMS causes muscle weakness and can be very debilitating and in some cases can be life-threatening. Catalyst completed a pivotal phase III trial last year for Firdapse and is currently filing a rolling NDA submission to the FDA. Catalyst believes that Firdapse has the potential to treat other neuromuscular disorders such as congenital myasthenic syndromes and certain forms of myasthenia gravis.
Additionally, Catalyst has two other drug candidates in their pipeline, both are GABA-AT inhibitors. These drugs are being studied as potential therapies for Tourette’s Disorder and infantile spasms, both of these diseases qualify as orphan drugs.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
Source:The NASDAQ OMX Group, Inc.